CoChat
Cited by 233

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study

Open access
Areia, Miguel, Mori, Yuichi, Correale, Loredana, Repici, Alessandro, Bretthauer, Michael, Sharma, Prateek, Taveira, Filipe, Spadaccini, Marco, Antonelli, Giulio, Ebigbo, Alanna, Kudo, Shin-ei, Arribas, Julia, Barua, Ishita, Kaminski, Michal F, Messmann, Helmut, Rex, Douglas K, Dinis-Ribeiro, Mário, Hassan, Cesare · 2022 · The Lancet Digital Health

Abstract

BACKGROUND: Artificial intelligence (AI) tools increase detection of precancerous polyps during colonoscopy and might contribute to long-term colorectal cancer prevention. The aim of the study was to investigate the incremental effect of the implementation of AI detection tools in screening colonoscopy on colorectal cancer incidence and mortality, and the cost-effectiveness of such tools. METHODS: We conducted Markov model microsimulation of using colonoscopy with and without AI for colorectal cancer screening for individuals at average risk (no personal or family history of colorectal cancer, adenomas, inflammatory bowel disease, or hereditary colorectal cancer syndrome). We ran the microsimulation in a hypothetical cohort of 100 000 individuals in the USA aged 50-100 years. The primary analysis investigated screening colonoscopy with versus without AI every 10 years starting at age 50 years and finishing at age 80 years, with follow-up until age 100 years, assuming 60% screening population uptake. In secondary analyses, we modelled once-in-life screening colonoscopy at age 65 years in adults aged 50-79 years at average risk for colorectal cancer. Post-polypectomy surveillance followed the simplified current guideline. Costs of AI tools and cost for downstream treatment of screening detected disease were estimated with 3% annual discount rates. The main outcome measures included the incremental effect of AI-assisted colonoscopy versus standard (no-AI) colonoscopy on colorectal cancer incidence and mortality, and cost-effectiveness of screening projected for the average risk screening US population. FINDINGS: In the primary analyses, compared with no screening, the relative reduction of colorectal cancer incidence with screening colonoscopy without AI tools was 44·2% and with screening colonoscopy with AI tools was 48·9% (4·8% incremental gain). Compared with no screening, the relative reduction in colorectal cancer mortality with screening colonoscopy with no AI was 48·7% and with screening colonoscopy with AI was 52·3% (3·6% incremental gain). AI detection tools decreased the discounted costs per screened individual from $3400 to $3343 (a saving of $57 per individual). Results were similar in the secondary analyses modelling once-in-life colonoscopy. At the US population level, the implementation of AI detection during screening colonoscopy resulted in yearly additional prevention of 7194 colorectal cancer cases and 2089 related deaths, and a yearly saving of US$290 million. INTERPRETATION: Our findings suggest that implementation of AI detection tools in screening colonoscopy is a cost-saving strategy to further prevent colorectal cancer incidence and mortality. FUNDING: European Commission and Japan Society of Promotion of Science.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2589-7500(22)00042-5

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 32

  1. Fitzmaurice, 2019, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study, JAMA Oncol, 5, 1749, 10.1001/jamaoncol.2019.2996 · DOI · Paper page
  2. Ladabaum, 2014, Colorectal testing utilization and payments in a large cohort of commercially insured US adults, Am J Gastroenterol, 109, 1513, 10.1038/ajg.2014.64 · doi:10.1038/ajg.2014.64
  3. Brenner, 2014, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies, BMJ, 348, 10.1136/bmj.g2467 · DOI · Paper page
  4. Lin, 2016, Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force, JAMA, 315, 2576, 10.1001/jama.2016.3332 · DOI · Paper page
  5. Shaukat, 2013, Long-term mortality after screening for colorectal cancer, N Engl J Med, 369, 1106, 10.1056/NEJMoa1300720 · DOI · Paper page
  6. de Moor, 2018, Colorectal cancer screening in the United States: trends from 2008 to 2015 and variation by health insurance coverage, Prev Med, 112, 199, 10.1016/j.ypmed.2018.05.001 · DOI
  7. Senore, 2019, Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test, J Med Screen, 26, 76, 10.1177/0969141318789710 · doi:10.1177/0969141318789710
  8. Ait Ouakrim, 2015, Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database, BMJ, 351
  9. Zorzi, 2015, Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy), Gut, 64, 1389, 10.1136/gutjnl-2014-307954 · DOI
  10. Kaminski, 2017, Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative, Endoscopy, 49, 378, 10.1055/s-0043-103411 · DOI · Paper page
  11. Kaminski, 2010, Quality indicators for colonoscopy and the risk of interval cancer, N Engl J Med, 362, 1795, 10.1056/NEJMoa0907667 · DOI · Paper page
  12. Kaminski, 2016, Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial, Gut, 65, 616, 10.1136/gutjnl-2014-307503 · DOI · Paper page
  13. Mori, 2021, Artificial intelligence in colonoscopy—now on the market. What's next?, J Gastroenterol Hepatol, 36, 7, 10.1111/jgh.15339 · DOI
  14. Ladabaum, 2019, Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years, Gastroenterology, 157, 137, 10.1053/j.gastro.2019.03.023 · DOI · Paper page
  15. Silva-Illanes, 2018, Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review, Value Health, 21, 858, 10.1016/j.jval.2017.11.010 · DOI
  16. Ladabaum, 2005, Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand, Gastroenterology, 129, 1151, 10.1053/j.gastro.2005.07.059 · DOI · Paper page
  17. Vatn, 1982, The prevalence of polyps of the large intestine in Oslo: an autopsy study, Cancer, 49, 819, 10.1002/1097-0142(19820215)49:4<819::AID-CNCR2820490435>3.0.CO;2-D · doi:10.1002/1097-0142(19820215)49:4<819::aid-cncr2820490435>3.0.co;2-d
  18. Ladabaum, 2001, Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis, Ann Intern Med, 135, 769, 10.7326/0003-4819-135-9-200111060-00007 · DOI
  19. Gupta, 2020, Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, 158, 1131, 10.1053/j.gastro.2019.10.026 · DOI · Paper page
  20. Ness, 1999, Utility valuations for outcome states of colorectal cancer, Am J Gastroenterol, 94, 1650, 10.1111/j.1572-0241.1999.01157.x · doi:10.1111/j.1572-0241.1999.01157.x · Paper page
  21. Djalalov, 2014, A review and meta-analysis of colorectal cancer utilities, Med Decis Making, 34, 809, 10.1177/0272989X14536779 · doi:10.1177/0272989x14536779
  22. Smith, 2001, The practice of discounting in economic evaluations of healthcare interventions, Int J Technol Assess Health Care, 17, 236, 10.1017/S0266462300105094 · DOI
  23. Bretthauer, 2016, Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial, JAMA Intern Med, 176, 894, 10.1001/jamainternmed.2016.0960 · DOI · Paper page
  24. Quintero, 2012, Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening, N Engl J Med, 366, 697, 10.1056/NEJMoa1108895 · DOI · Paper page
  25. Kaminski, 2015, Design of the Polish Colonoscopy Screening Program: a randomized health services study, Endoscopy, 47, 1144, 10.1055/s-0034-1392769 · DOI
  26. Heijnsdijk, 2019, All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: a review and modeling study, Cancer Med, 8, 6127, 10.1002/cam4.2476 · DOI
  27. Gupta, 2020, Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer, Gastrointest Endosc, 91, 463, 10.1016/j.gie.2020.01.014 · DOI · Paper page
  28. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69
  29. Shung, 2020, How artificial intelligence will impact colonoscopy and colorectal screening, Gastrointest Endosc Clin N Am, 30, 585, 10.1016/j.giec.2020.02.010 · DOI
  30. Pilonis, 2020, Long-term colorectal cancer incidence and mortality after a single negative screening colonoscopy, Ann Intern Med, 173, 81, 10.7326/M19-2477 · DOI
  31. Kaminski, 2017, Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death, Gastroenterology, 153, 98, 10.1053/j.gastro.2017.04.006 · DOI · Paper page
  32. Hassan, 2015, Efficacy and cost-effectiveness of screening colonoscopy according to the adenoma detection rate, United European Gastroenterol J, 3, 200, 10.1177/2050640614565199 · doi:10.1177/2050640614565199

Cited by

See all 233

Metadata

Authors
Areia, M., Mori, Y., Correale, L., Repici, A., Bretthauer, M., Sharma, P., Taveira, F., Spadaccini, M., Antonelli, G., Ebigbo, A., Kudo, S.-E., Arribas, J., Barua, I., Kaminski, M. F., Messmann, H., Rex, D. K., Dinis-Ribeiro, M., & Hassan, C.
Venue
The Lancet Digital Health
Publisher
Elsevier BV
Published
2022-06
Volume
4
Issue
6
Pages
e436-e444
ISSN
2589-7500 (ISSN-L)
OpenAlex
W4223959434
Cited by
233
References
13
FWCI
17.67
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Medtronic
  • Boston Scientific Corporation
  • European Commission (101026196)
  • Japan Society for the Promotion of Science (19KK0421)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study. https://app.cochat.ai/papers/10.1016/s2589-7500(22)00042-5
The paper
Areia, M., Mori, Y., Correale, L., Repici, A., Bretthauer, M., Sharma, P., Taveira, F., Spadaccini, M., Antonelli, G., Ebigbo, A., Kudo, S.-E., Arribas, J., Barua, I., Kaminski, M. F., Messmann, H., Rex, D. K., Dinis-Ribeiro, M., & Hassan, C. (2022). Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study. The Lancet Digital Health. https://doi.org/10.1016/s2589-7500(22)00042-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.